The DEA has moved CBD prescription drugs with THC levels below .01% to a Schedule 5 drug after the FDA’s approval of Epidolex. However, despite the reschedule, cannabis still remains a Schedule 1 substance. READ MORE
(By accessing, browsing or using the pages below, you agree to the Blog Conditions of Use/Disclaimer available under "Links.")
Contributors
Contributors
RELATED EVENTS
RELATED EVENTS
August 27
2019
2019
Posts
Making sense of California’s ban on industrial hemp in food products
August 13, 2018
While California law allows marijuana-derived CBD in food products, CBD from industrial hemp does not have the same privilege and faces a shrinking market both inside and outside the Golden State. READ MORE
Cannabis in animal supplements: A hazy proposition
January 9, 2017
Until further guidance comes from the FDA, the cannabis industry should tread carefully in the production and marketing of cannabis-containing animal supplements. Supplement makers should take care to avoid drug-like claims for their products and adhere to strict food safety regulations in the manufacturing process. READ MORE
The silver lining in the DEA’s refusal to reclassify cannabis
August 15, 2016
Although the DEA announced last week that it would not reschedule cannabis, the decision did come with promising news of enhanced research opportunities that could bolster the cannabis industry's long-term growth. READ MORE
Thompson Coburn takes stage at Cannabis Business Summit
Carl Rowley
July 6, 2016
Carl Rowley of Thompson Coburn’s cannabis practice attended the 2016 Cannabis Business Summit hosted by the National Cannabis Industry Association in Oakland, Calif., in late June. READ MORE
Cannabis Conflicts Part II: The problem with state and federal food labeling requirements
May 20, 2015
Illinois’ “Compassionate Use of Medical Cannabis Pilot Program Act” (the “CUMCPPA”) creates an entire regime of laws, regulations and procedures by which individuals and companies are building medical cannabis growing facilities and dispensaries. READ MORE
Thompson Coburn advises clients on state laws governing the business of cannabis to facilitate compliance with those state laws. Federal laws concerning cannabis currently conflict with state laws in states that have legalized cannabis or possession of cannabis. Although federal enforcement policy may at times defer to these states’ laws and not enforce conflicting federal laws, interested businesses and individuals should be aware that compliance with state law in no way assures compliance with federal law, and there is a risk that conflicting federal laws may be enforced in the future. In addition to this Cannabis-specific note, readers should review Thompson Coburn’s Conditions of Use / Disclaimers page containing other important information.